SCRI

Nashville, Tennessee 37203

1 studies enrolling now · 14 studies all time

What they study most

ALL, AML, Advanced Non-clear Cell Renal Cell Carcinoma, Advanced Solid Tumor and Lymphoma Malignancies, Anal Squamous Cell Carcinoma, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, B-Cell Lymphoma, Bladder Cancer, Blast Crisis, Cervical Squamous Cell Carcinoma, Chronic Lymphocytic Leukemia

Studies at this site

• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas — Recruiting now
• Connect® MM- The Multiple Myeloma Disease Registry — Stopped early
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer — Stopped early
• Sarah Cannon Outcomes Registry — Withdrawn before enrolling
• iCORE: Collaborative Orthopedics Outcomes Registry — Withdrawn before enrolling
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma — Stopped early
• Study of HL-085 in Patients With Advanced Solid Tumor Tumors — Completed
• A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies — Completed
• Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors — Completed
• Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry — Completed
• Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma — Completed
• A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors — Completed
• Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma — Completed
• Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies — Completed